report cf franchis revenu vs consensu non-
gaap ep vs consensu manag reiter updat
revenu guidanc provid time trikafta earli approv trikafta launch
underway first patient receiv therapi expect industry-
lead growth remain top larg cap pick
vertex report cystic fibrosi cf franchis revenu q/q
y/i line consensu estim revenu includ
kalydeco sale q/q y/i orkambi q/q y/i
symdeko revenu q/q y/i cf franchis y/i growth driven
on-going uptak symdeko symkevi ex-u combin non-gaap
sg vs yield non-gaap ep ahead
consensu
last week associ earli approv trikafta vertex increas
net product revenu guidanc previous non-
 sg guidanc unchang vertex revenu guidanc
assum sale market compani alreadi achiev reimburs
includ recent agreement scotland spain australia subsequ fund
agreement attain england -- estim market vertex --
like modest impact revenu medic becom avail
england end novemb base recent approv reimburs
decis cf franchis estim increas
y/i y/i respect
non-gaap ep est similarli increas
last week vertex announc fda approv trikafta elexacaftor/tezacaftor/
ivacaftor treatment cystic fibrosi cf patient age year older
least one mutat approv came approxim five month trikafta
march pdufa two month accept nda august
approv mark first time het min patient approxim peopl
age medicin treat underli caus diseas vertex
estim anoth approxim cf patient current elig one
compani fda-approv cf medicin also elig trikafta
tonight vertex disclos first patient treat trikafta
manag expect revenu growth driven mostli treatment
new het min patient though signific proport patient current kalydeco
orkambi symdeko also switch trikafta trikafta launch affect
capac constraint cf center task initi larg volum
elig patient onto therapi launch may take longer reach full penetr
vertex previou launch particularli kalydeco reach full penetr
 market within two quarter nonetheless expect trikafta uptak
rapid compar product recent confer
survey physician anticip least het min patient popul
would trikafta month fda approv
pleas see page report import disclosur
vertex develop portfolio therapi cystic fibrosi breakthrough
treatment cf patient harbor least allel cftr potenti
kalydeco first approv patient gate partial loss function
mutat orkambi cftr corrector lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
trikefta contain gener corrector well tezacaftor ivacaftor
produc impress ph data appear like improv qualiti life extend
life span patient trikefta fda approv octob
file review model assum cystic fibrosi patient
one vertex therapi drive nearli franchis sale dcf-base price
target
data ph i/ii sickl
phase ii data
like ema approv trikafta
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
rest pipelin contribut
cystic
fibrosi patient one vertex
therapi drive
franchis sale
franchis maintain exclus
anoth vertex pipelin program
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
vertex face meaning competit
vertex leader treatment cystic fibrosi symdeko orkambi kalydeco
standard therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener strike phase data
tripl combin regimen incorpor second gener corrector
min patient regimen approv two month fda review octob
appear repres true breakthrough treatment improv qualiti
life extend life span cystic fibrosi world-wide moreov patent
protect late vertex franchis long commerci life
early-stag pipelin includ candid antitrypsin defici pain sickl
cell diseas beta-thalassemia focal segment glomerulosclerosi initi proof-of-
concept data program anticip
also last week vertex announc formal reimburs agreement england
nation health servic nh allow elig cystic fibrosi patient england
access orkambi symkevi expand access kalydeco specif patient
age year older homozyg mutat may receiv
orkambi patient age year older either homozyg
mutat one mutat one licens mutat may
receiv symekevi agreement also expand access kalydeco includ patient
age year older mutat patient age month
older one nine licens gate mutat medic
avail england novemb within day announc vertex
estim peopl cystic fibrosi england approxim
would elig agreement compani expect
elig patient initi therapi base uptak seen geographi
persist also rang thu estim patient england
might one current approv cftr modul base term recent
reimburs deal england estim annual kalydeco orkambi symkevi sale
england would approxim
vertex submit ema trikafta pend chmp recommend
ema approv vertex plan submit trikafta januari
rational wait earli two-fold first allow vertex collect
addit long-term data open-label extens studi second process
review methodolog vertex hope method review
may make chang valuat methodolog would better analyz benefit
potent agent seriou orphan diseas trikafta
current program clinic develop mani expect gener
meaning data
vertex first candid antitrypsin complet sad
mad studi healthi volunt though compani releas phase
result tonight vertex announc phase ii proof-of-concept dose-find studi
approxim patient defici two mutat set initi
phase ii clinic data includ level liver biopsi data expect
base preclin data vertex expect correct fold reduc
aggreg form liver allow protein travel lung vertex
also advanc second small molecul corrector phase develop
risk mitig purpos vertex may take multipl candid phase ii done
cf
enrol on-going ph i/ii studi sickl cell diseas scd
beta thalassemia approxim six site enrol beta thalassemia patient
approxim enrol scd tonight vertex announc first safeti
efficaci data hemoglobin level beta thalassemia scd patient releas
pain vertex identifi sever select inhibitor compani intend
obtain clinic data multipl compound determin best molecul
advanc late-stag develop phase trial novel inhibitor
on-going healthi volunt
vertex initi phase studi oral small molecul
focal segment glomerulosclerosi fsg fsg character proteinuria
patient typic progress develop impair kidney function vertex estim
approxim patient fsg homozyg
mutat phase studi expect complet assum phase data
posit vertex plan initi phase ii trial reduct proteinuria
primari endpoint vertex sever inhibitor candid treatment
fsg preclin develop
final initi phase ii dose-rang studi once-daili potenti
monotherapi support develop part once-daili tripl clinicaltri gov
list primari complet date june compani plan initi
phase develop once-daili tripl regimen also evalu
combin third-gener corrector tezecaftor phase ii studi
accord clinicaltri gov trial expect complet decemb impli
data earli initi phase program later year
vertex leader develop candid treat cystic fibrosi model
assum cystic fibrosi patient one vertex therapi
drive almost franchis sale base promis tripl regimen
project revenu compound-annual-growth-rate non-gaap ep compound-annual-growth-rate
highest larg cap biotech patent protect exclus late
tripl regimen long lucr commerci live moreov
anticip potenti non-cf pipelin becom clear next
month least candid earli clinic test year-
end larg cap univers middl growth prospect think fundament
posit vertex must biotech larg cap growth investor expect
vertex stock appreci price target tripl regimen approach commerci
launch vertex non-cf pipelin gener proof-of-concept dcf-base price
target
vertex leader discoveri develop candid treat
cystic fibrosi vertex develop portfolio therapi cystic fibrosi
standard care treatment cf patient
harbor least allel vertex first cystic fibrosi commerci
product kalydeco ivacaftor cftr potenti compound
kalydeco approv fda januari patient non-
gate mutat mutat addit residu function
mutat ad label seri supplement approv vertex
subsequ develop regimen contain kalydeco cftr corrector
lumacaftor tezacaftor broaden use beyond partial loss-of-funct
mutat includ cystic fibrosi patient homozyg
mutat orkambi lumacaftor ivacaftor succeed two pivot trial
june approv juli symdeko tezacaftor
ivacaftor produc posit data two phase trial march
fda approv februari european approv came novemb
brand name symkevi improv potenc orkambi
symdeko homozygot effect patient
one copi allel vertex develop second gener
corrector act synergist lumacaftor tezacaftor
complet correct fold defect cftr trikafta
combin tezacaftor ivacaftor second-gener once-daili
corrector produc impress phase data approv
fda octob brief two month review trikafta appear
repres true breakthrough treatment improv qualiti life
extend life span patient cystic fibrosi
world-wide least one copi mutat moreov
second-gener corrector expect patent protect
vertex franchis long commerci life model
assum cystic fibrosi patient one vertex therapi
drive almost franchis sale impli industry-
lead growth dcf-base price target remain top
initi data phase i/ii studi sickl cell diseas beta-thalassemia
phase ii data first corrector
initi phase ii poc trial fsg
like releas data phase ii tezacaftor
possibl ema approv eu
possibl in-licens acquisit addit product candid
cowen compani
cowen compani
statesnumb patient diagnos patient penetr patient kalydeco per patient patient gate gate penetr patient kalydeco per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/trikafta cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu kalydeco kalydeco orkambi orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
cowen compani
fy dec except per symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling interestnet lncome exclud soe exclud soe expens net share share stock option expens cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu two relat product kalydeco
orkambi forecast sale franchis difficult outlook could
alter new safety/efficaci find emerg competit alter medic
treatment paradigm chang pricing/reimburs environ vertex
stock price could also affect chang outlook key pipelin program
includ second gener corrector evalu market potenti
drug yet approv particularli riski
